Characterizing the endometriosis patient journey in a German cohort: experiences from the LIDEA Registry
Womens Health
BIOGRAPHY
Klaas Heinemann
Klaas Heinemann leads ZEG Berlin in providing data of quality and integrity to pharmaceutical companies. Klaas sets the organization’s overall direction for its work in pharmacoepidemiology and drug safety.
Klaas Heinemann is a physician and epidemiologist who has headed ZEG Berlin since 2009 and sits on the Kantar Health Europe management board. The principal investigator for many studies, Klaas provides strategic direction as ZEG-Berlin diversifies beyond women’s health studies to bring its data methodology to other realms of health.
Klaas trained in internal medicine at Charite University Hospital, Berlin before completing postgraduate masters degrees in business and administration (Berlin School of Economics, Berlin), and epidemiology (London School of Hygiene and Tropical Medicine, London). Prior to his appointment as managing director, Klaas was an external consultant for ZEG Berlin. Previously he worked in the US and Germany as a Medical Expert in Global Medical Affairs at Schering AG and later Bayer Pharma, planning and managing clinical research focusing on Phase III clinical studies and post-market phase IV study design.
PUBLICATIONS
2026
Polished but pointless? Assessing the potential of gold and silver-alloy IUDs versus copper-only devices in a large multinational cohort (EURAS- LCS12)
Womens Health
Medical habit or necessity? Investigating misoprostol use for IUD insertion in Europe
Womens Health
Adherence to National Guidelines for Post-IUD Insertion Check-Up: Findings from the Large European Real-World EURAS-LCS12 Study
Womens Health
2025
Endometriosis and risk of depression among oral contraceptive users: a pooled analysis of cohort studies from 13 countries
Endometriosis
Population characteristics of intrauterine device users in real-world clinical practice across Europe – insights from the EURAS-LCS12 study
IUD
Real-world use of antispasmodic drugs during IUD insertion – insights from the large observational study EURAS-LCS12
IUD
Risk of venous thromboembolism associated with chlormadinone acetate- and levonorgestrel-containing combined oral contraceptives – Insights from the retrospective RIVET-RCS study
IUD
Use of oral medications prior to IUD insertion – Trends and associations of patient characteristics in a large observational study in Europe (EURAS-LCS12)
IUD
2024
Does the shape of the copper intrauterine device play a role in expulsion? Results from the ongoing European Active Surveillance Study on LCS12
IUD
Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data
Oral contraceptive
Time to Diagnose Endometriosis: Current Status, Challenges and Regional Characteristics – A Systematic Literature Review
Endometriosis
Unravelling the Causal Relationship between Endometriosis and the Risk for Developing Venous Thromboembolism: A Pooled Analysis
Endometriosis
2023
How did regional lockdowns during the COVID-19 pandemic affect recruitment into a large multinational cohort study of intrauterine device users?
IUD
2022
Pregnancy and pregnancy outcomes in a prospective cohort study: Final Results from the Nexplanon Observational Risk Assessment Study (NORA)
Other